Review article · 2020 · Open access

What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials

Szofia Bullain, Rachelle Smith Doody

Journal of Neurochemistry, 155(2), 120–136 · Published 11 April 2020 · DOI 10.1111/jnc.15023

Open PDFView at the publisherCite this paper

In brief

“What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials” is a 2020 review article by Szofia Bullain and Rachelle Smith Doody, published in Journal of Neurochemistry. OpenAlex counts 41 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Journal of Neurochemistry.

Citations
41
Most cited in
2023 (13)
Field-weighted impact
0.97
References
138
Authors
2

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder with no approved disease-modifying therapy (DMT). In this review, we summarize the various past approaches taken in an attempt to find treatments capable of altering the long-term course for individuals with AD, including: translating epidemiological observations into potential treatment options; seeking a single-treatment approach across the continuum of AD severity; utilizing biomarkers for assessing target engagement; using biomarkers as early surrogates of clinical efficacy; and enriching study populations to demonstrate adequate placebo decline during the limited duration of clinical trials. Although targeting the amyloid-β (Aβ) pathway has been central to the search for an effective DMT, to date, trials of anti-Aβ monoclonal antibodies have failed to consistently demonstrate significant clinical efficacy. Key learnings from these anti-Aβ trials, as well as the trials that came before them, have shifted the focus within clinical development programs to identifying target populations thought most likely to benefit from treatments (i.e., individuals at an earlier stage of disease). Other learnings include strategies to increase the likelihood of showing measurable improvements within the clinical trial setting by better predicting decline in placebo participants, as well as developing measures to quantify the needed treatment exposure (e.g., higher doses). Given the complexity associated with AD pathology and progression, treatments targeting non-amyloid AD pathologies in combination with anti-amyloid therapies may offer an alternative for the successful development of DMTs.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Bullain, S., & Doody, R. S. (2020). What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials. Journal of Neurochemistry, 155(2), 120–136. https://doi.org/10.1111/jnc.15023

MLA 9

Bullain, Szofia, and Rachelle Smith Doody. “What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials.” Journal of Neurochemistry, vol. 155, no. 2, 2020, pp. 120–136. https://doi.org/10.1111/jnc.15023.

Chicago

Bullain, Szofia and Rachelle Smith Doody. 2020. “What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials.” Journal of Neurochemistry 155 (2): 120–136. https://doi.org/10.1111/jnc.15023.

Harvard

Bullain, S. and Doody, R. S. (2020) ‘What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials’, Journal of Neurochemistry, 155(2), pp. 120–136. doi:10.1111/jnc.15023.

IEEE

S. Bullain and R. S. Doody, “What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials,” Journal of Neurochemistry, vol. 155, no. 2, pp. 120–136, 2020, doi: 10.1111/jnc.15023.

BibTeX

@article{bullain2020what,
  title     = {{What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials}},
  author    = {Bullain, Szofia and Doody, Rachelle Smith},
  journal   = {Journal of Neurochemistry},
  year      = {2020},
  volume    = {155},
  number    = {2},
  pages     = {120--136},
  doi       = {10.1111/jnc.15023},
  url       = {https://doi.org/10.1111/jnc.15023}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202055
202155
20221111
20231313
202411
202544
202622

Its field-weighted citation impact is 0.97: it has been cited 0.97 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • disease-modifying therapy
  • anti-amyloid monoclonal antibodies
  • amyloid-beta
  • risk factor intervention
  • biomarkers
  • target engagement
  • surrogate endpoints

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Bullain, S., & Doody, R. S. (2020). What works and what does not work in Alzheimer’s disease? From interventions on risk factors to anti‐amyloid trials. Journal of Neurochemistry, 155(2), 120–136. https://doi.org/10.1111/jnc.15023

How many times has this paper been cited?

41 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal of Neurochemistry: sign in and open the PDF from this page.

Who wrote this paper?

Szofia Bullain, Rachelle Smith Doody.

What is the DOI of this paper?

10.1111/jnc.15023, permanently at https://doi.org/10.1111/jnc.15023. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.